Media stories about Inovio Pharmaceuticals (NASDAQ:INO) have been trending somewhat positive recently, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Inovio Pharmaceuticals earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.397625466478 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Stock’s Technical Analysis: Inovio Pharmaceuticals Inc (NASDAQ: INO) – Alpha Beta Stock (alphabetastock.com)
- Average True Range (ATR) to Consider Before Investment – Inovio Pharmaceuticals, Inc., (NASDAQ: INO) – Stock Watch (stocksnewstimes.com)
- Inovio Pharmaceuticals (INO) Given a $13.00 Price Target by HC Wainwright Analysts (americanbankingnews.com)
- Inovio Pharma (INO): Checkpoint Combo Results In Significant Preclinical Improvement – HC Wainwright – StreetInsider.com (streetinsider.com)
- BRIEF-Inovio Pharma Cancer Vaccine Shows Promise In Preclinical Trial (in.reuters.com)
Inovio Pharmaceuticals (INO) opened at $4.63 on Wednesday. Inovio Pharmaceuticals has a 12-month low of $4.20 and a 12-month high of $9.86.
A number of research analysts have weighed in on INO shares. Citigroup started coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, September 6th. They set a “buy” rating and a $10.00 price target on the stock. BidaskClub cut shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 27th. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, October 25th. Maxim Group reaffirmed a “buy” rating and set a $12.00 price target on shares of Inovio Pharmaceuticals in a research report on Tuesday, September 12th. Finally, Zacks Investment Research cut shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. Inovio Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $19.16.
COPYRIGHT VIOLATION WARNING: “Inovio Pharmaceuticals (INO) Receiving Somewhat Positive News Coverage, Study Shows” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/11/29/inovio-pharmaceuticals-ino-receiving-somewhat-positive-news-coverage-study-shows.html.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.